Metal–Organic Frameworks: Unconventional Nanoweapons against COVID
Source abstract
Abstract
The SARS-CoV-2 (COVID-19) pandemic outbreak led to enormous social and economic repercussions worldwide, felt even to this date, making the design of new therapies to combat fast-spreading viruses an imperative task. In the face of this, diverse cutting-edge nanotechnologies have risen as promising tools to treat infectious diseases such as COVID-19, as well as challenging illnesses such as cancer and diabetes. Aside from these applications, nanoscale metal-organic frameworks (nanoMOFs) have attracted much attention as novel efficient drug delivery systems for diverse pathologies. However, their potential as anti-COVID-19 therapeutic agents has not been investigated. Herein, we propose a pioneering anti-COVID MOF approach by studying their potential as safe and intrinsically antiviral agents through screening various nanoMOF. The iron(III)-trimesate MIL-100 showed a noteworthy antiviral effect against SARS-CoV-2 at the micromolar range, ensuring a high biocompatibility profile (90% of viability) in a real infected human cellular scenario. This research effectively paves the way toward novel antiviral therapies based on nanoMOFs, not only against SARS-CoV-2 but also against other challenging infectious and/or pulmonary diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Nanoplatforms for cancer theranostics · COVID-19 Clinical Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Advanced Porous Materials Unit, IMDEA Energy, Ramón de la Sagra 3, 28935 Móstoles-Madrid, Spain
Wallenberg Initiative Materials Science for Sustainability, Department of Materials and Environmental Chemistry
Stockholm University
Funding
Comunidad de Madrid · European Regional Development Fund · HORIZON EUROPE Marie Sklodowska-Curie Actions
References (70)
Show source-provided references
1. 10.5089/9798400205996.00110.5089/9798400205996.001 ↗
2. World Health Organization(WHO). World Health Organization. [Internet]. https://data.who.int/dashboards/covid19/deaths. Accessed date (April 2024).
3. 10.3389/fphar.2023.118246510.3389/fphar.2023.1182465 ↗
4. US Food and Drug Administration (FDA). Remdesivir (Veklury) [package insert]: Highlights of prescribing information. Remdesivir (Veklury) [package insert]: Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214787s019lbl.pdf. Accessd date (March 2024).
5. 10.1038/s41565-022-01174-510.1038/s41565-022-01174-5 ↗
6. 10.1016/j.isci.2022.10506610.1016/j.isci.2022.105066 ↗
7. 10.1002/wnan.170710.1002/wnan.1707 ↗
8. 10.3390/nano1206099010.3390/nano12060990 ↗
9. 10.1039/D1SC04515F10.1039/D1SC04515F ↗
10. 10.1039/D1SC03526F10.1039/D1SC03526F ↗
11. 10.1186/s12951-022-01542-210.1186/s12951-022-01542-2 ↗
12. 10.1080/14756366.2022.210841710.1080/14756366.2022.2108417 ↗
13. 10.3390/pharmaceutics1312217410.3390/pharmaceutics13122174 ↗
14. 10.1039/D3NR05776C10.1039/D3NR05776C ↗
15. 10.1007/s13346-023-01500-x10.1007/s13346-023-01500-x ↗
16. 10.1016/j.ccr.2023.21564310.1016/j.ccr.2023.215643 ↗
17. 10.1038/nmat260810.1038/nmat2608 ↗
18. 10.1016/j.ccr.2019.02.03210.1016/j.ccr.2019.02.032 ↗
19. 10.1039/D1SC04112F10.1039/D1SC04112F ↗
20. 10.1002/adfm.20230858910.1002/adfm.202308589 ↗
21. 10.3390/nano1202027710.3390/nano12020277 ↗
22. 10.1021/acsami.3c0092210.1021/acsami.3c00922 ↗
23. 10.1002/adhm.20210041010.1002/adhm.202100410 ↗
24. 10.1002/chem.20220313610.1002/chem.202203136 ↗
25. 10.1039/D3SC00106G10.1039/D3SC00106G ↗
26. 10.1021/acsami.2c2118710.1021/acsami.2c21187 ↗
27. 10.1016/j.micromeso.2023.11297510.1016/j.micromeso.2023.112975 ↗
28. 10.1039/D3CC00894K10.1039/D3CC00894K ↗
29. 10.1021/acsami.2c0642010.1021/acsami.2c06420 ↗
30. 10.2147/IJN.S22166710.2147/IJN.S221667 ↗
31. 10.1039/C3TB20832J10.1039/C3TB20832J ↗
32. 10.1021/jacs.0c0752510.1021/jacs.0c07525 ↗
33. 10.3390/nu1011175610.3390/nu10111756 ↗
34. 10.1039/B704325B10.1039/B704325B ↗
35. 10.1021/acsami.0c0735610.1021/acsami.0c07356 ↗
36. 10.1039/C9NR08127E10.1039/C9NR08127E ↗
37. 10.1021/ic800538r10.1021/ic800538r ↗
38. 10.1126/science.113797510.1126/science.1137975 ↗
39. 10.1021/ja206936e10.1021/ja206936e ↗
40. 10.1021/ja805795310.1021/ja8057953 ↗
41. 10.1021/acs.chemmater.6b0511510.1021/acs.chemmater.6b05115 ↗
42. 10.1021/ja409886210.1021/ja4098862 ↗
43. 10.1002/chem.20140538010.1002/chem.201405380 ↗
44. 10.1021/acsami.0c1090010.1021/acsami.0c10900 ↗
45. 10.26434/chemrxiv-2022-h353010.26434/chemrxiv-2022-h3530 ↗
46. 10.1038/s44221-023-00070-z10.1038/s44221-023-00070-z ↗
47. 10.1016/j.cell.2020.02.05210.1016/j.cell.2020.02.052 ↗
48. 10.1021/acsanm.0c0197810.1021/acsanm.0c01978 ↗
49. 10.1186/s42269-021-00487-010.1186/s42269-021-00487-0 ↗
50. 10.1002/cbic.20210018610.1002/cbic.202100186 ↗
51. 10.2217/nnm.15.16810.2217/nnm.15.168 ↗
52. 10.1093/jpp/rgab10210.1093/jpp/rgab102 ↗
53. 10.1002/adhm.20120045410.1002/adhm.201200454 ↗
54. 10.1039/C7TB01933E10.1039/C7TB01933E ↗
55. 10.3390/molecules2809377210.3390/molecules28093772 ↗
56. 10.1016/j.biopha.2023.11513210.1016/j.biopha.2023.115132 ↗
57. 10.1038/nrd436310.1038/nrd4363 ↗
58. 10.1007/s40336-014-0053-310.1007/s40336-014-0053-3 ↗
59. National Center for Biotechnology Information. PubChem. Compound Summary for CID 7489, Terephthalic acid. https://pubchem.ncbi.nlm.nih.gov/compound/Terephthalic-acid. Accessed date (February 2024).
60. Park C. · 2000
61. 10.1021/la501255510.1021/la5012555 ↗
62. 10.1016/j.ccr.2015.08.00810.1016/j.ccr.2015.08.008 ↗
63. Wang, Y.; Huang, J.; Sun, Y.; Stubbs, D.; He, J.; Li, W.; Wang, F.; Liu, Z.; Ruzicka, J. A.; Will, E.; Rayman, M. P.; Wan, X.; Zhang, J. Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID- 19. The COVID-19 Resource Centre Is Hosted on Elsevier Connect, the Company ’ S Public News and Information, 2020.
64. 10.1016/j.chempr.2020.08.00110.1016/j.chempr.2020.08.001 ↗
65. 10.1039/C5TB01223F10.1039/C5TB01223F ↗
66. 10.1002/ejic.20120071010.1002/ejic.201200710 ↗
67. 10.3390/ma1306146910.3390/ma13061469 ↗
68. 10.1016/j.materresbull.2017.10.03810.1016/j.materresbull.2017.10.038 ↗
69. 10.3390/ph1404033210.3390/ph14040332 ↗
70. US Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed date (April 2024).